Dabrafenib

Contraindicated

Dabrafenib Ketoconazole Topical Extina® Foam Increased CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details

Major

Dabrafenib Acetaminophen And Codeine Capital® & Codeine Explained Reduced codeine and morphine exposure, reduced opioid efficacy and precipitation of opioid withdrawal Details Dabrafenib Abametapir Explained Increased exposure of CYP3A4 substrate Details Dabrafenib Omeprazole Gastrobim Explained Reduced CYP2C19 sensitive substrate exposure Details Dabrafenib Amitriptyline Elavil Explained An increased risk of QT interval prolongation Details Dabrafenib Sertraline Explained An increased risk of QT interval prolongation Details Dabrafenib Buprenorphine Belbuca Explained Reduced buprenorphine exposure, reduced efficacy of buprenorphine and an increased risk of QT interval prolongation Details Dabrafenib Relugolix Orgovyx Explained Increased risk of QT interval prolongation Details Dabrafenib Simvastatin Flolipid Explained Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Abemaciclib Verzenio Explained Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Acalabrutinib Calquence Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Dabrafenib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation Details Dabrafenib Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Dabrafenib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation Details Dabrafenib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation Details Dabrafenib Atogepant Qulipta Reduced atogepant exposure Details Dabrafenib Avapritinib Ayvakit Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Azithromycin AzaSite An increased risk of QT interval prolongation Details Dabrafenib Atorvastatin Atorvaliq Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Cariprazine Vraylar Explained Effects on the cariprazine exposure has not been evaluated and the net effect is unclear Details Dabrafenib Abiraterone Abirtega Increased dabrafenib exposure Details Dabrafenib Aficamten Reduced aficamten exposure and reduced efficacy of aficamten Details Dabrafenib Alfuzosin UroXatral An increased risk of QT interval prolongation Details Dabrafenib Amlodipine Amvaz® Reduced amLODIPine exposure Details Dabrafenib Anagrelide Agrylin An increased risk of QT interval prolongation Details Dabrafenib Avanafil Stendra Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Bedaquiline Sirturo Reduced CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Dabrafenib Bosutinib Bosulif Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Budesonide Entocort Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Budesonide Nasal Spray Rhinocort Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Budesonide Oral Inhalation Pulmicort Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Cabozantinib Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Dabrafenib Cabozantinib (Thyroid Cancer) Cabometyx Reduced cabozantinib exposure and reduced efficacy of cabozantinib Details Dabrafenib Chloroquine Aralen® An increased risk of QT interval prolongation Details Dabrafenib Cobimetinib Cotellic Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Cyclosporine Injection Atopica Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Cyclosporine Ophthalmic Cequa Reduced sensitive CYP3A4 substrate exposure Details Dabrafenib Daprodustat Jesduvroq Reduced CYP2C8 sensitive substrate exposure and an increase risk of potential loss of efficacy Details Dabrafenib Dasatinib Phyrago Reduced CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details